With fundamentals solidly in place and adding more jobs to the manufacturing graveyard shift, Cepheid's (NASDAQ:CPHD) momentum appears to be slowly growing.
Wedbush noted, "Strong hiring trend consistent with strong fundamentals; New graveyard manufacturing shift postings, a positive sign in our view...We are slightly more encouraged by the recent manufacturing job postings and continued VA momentum of late, plus the recent WHO endorsement of the company's TB test, which helps to reduce near-term guidance risk. We are remaining NEUTRAL until we get more comfortable with the 2011 instrument placement opportunity, TB rollout, and potential upside from C.diff."
Wedbush maintains a "Neutral" on Cepheid, which closed Friday at $22.75, down $0.43, or 1.86 percent Wedbush has a price target of $23 on Cepheid.
No comments:
Post a Comment